Clinical trials: Myeloma, Plasma-Cell
Multiple Myeloma
Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma
The present trial is designed as a phase II study that aims at estimating the efficacy of the combination of bendamustine, bortezomib and dexamethasone in relapsed/refractory multiple myeloma (MM). The response rate, i.e.
- Trial name
- BVD (NCT01045681)
- Testing
- Bendamustine, Velcade and Dexamethasone
- Where
- 37 sites in France
- Volunteers
- 75 people
- Sponsor
- Intergroupe Francophone du Myelome
Multiple Myeloma
Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma
This study will assess the ability of Doxorubicin, Vincristine and Dexamethasone plus arsenic trioxide to achieve an overall response rate of greater than 60%.
- Trial name
- NCT00201695
- Testing
- Doxil®, Vincristine, Dexamethasone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Relapsed and/or Refractory Multiple Myeloma
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma
This will be a Phase 1 Open-Label, dose escalation of MT-0169 (an Engineered toxin body (ETB) in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT04017130
- Testing
- MT-0169
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Molecular Templates, Inc.
Myeloma
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
The main purpose of this study is to see whether pomalidomide can help people with myeloma. Researchers also want to find out if pomalidomide is safe and tolerable.
- Trial name
- NCT01432600
- Testing
- Pomalidomide, Dexamethasone, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Relapsed/Refractory Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
Multiple myeloma (MM) is an incurable disease characterized by the growth of monoclonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease state of etentamig in adult…
- Trial name
- NCT05286229
- Testing
- Etentamig
- Where
- 6 sites in Japan
- Volunteers
- 8 people
- Sponsor
- AbbVie
Multiple Myeloma and Plasma Cell Neoplasm
Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00482495
- Testing
- bevacizumab, gene expression analysis, protein expression analysis
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439175
- Testing
- Taselisib
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Infection
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies
RATIONALE: Antimicrobial solution comprising trimethoprim-sulfamethoxazole, edetate calcium disodium, and ethanol may help prevent blockages and infections from forming in patients with central venous access catheters or…
- Conditions
- Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma
- Trial name
- NCT01101412
- Testing
- Edetate Calcium Disodium, Ethanol, Trimethoprim-sulfamethoxazole
- Sponsor
- M.D. Anderson Cancer Center
Multiple Mieloma
Infection Surveillance of R/R Multiple Myeloma Patients Treated With Elranatamab as Clinical Practice in Italy
The primary objective of this study is to measure the infection rate and presentation pattern in first 12 months of therapy with elranatamab as standard clinical practice in adult patients with Relapsed/Refractory Multiple…
- Trial name
- RISE (NCT07564128)
- Volunteers
- 50 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
This phase II MATCH treatment trial identifies the effects of trametinib and dabrafenib in patients whose cancer has genetic changes called BRAF V600 mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439292
- Testing
- Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Refractory Multiple Myeloma
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data.
- Trial name
- NCT05053607
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Pack Health
Myelodysplastic Syndrome, Multiple Myeloma
A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)
The purpose of this trial is to evaluate the safety, tolerability, and efficacy of pembrolizumab (MK-3475, KEYTRUDA®) and pembrolizumab in combination with lenalidomide (Cohort 5 only) in hematologic malignancies.
- Conditions
- Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- NCT01953692
- Testing
- Pembrolizumab, Lenalidomide 20 mg, Lenalidomide 25 mg
- Volunteers
- 197 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphoma, Leukemia
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological…
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Venous Thromboembolic Disease
- Trial name
- HEM-DOAC (NCT07270263)
- Testing
- Apixaban, Rivaroxaban, low molecular weight heparin (enoxaparin sodium)
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Gdansk
Lymphoma, Multiple Myeloma
Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies
Platelet concentrates (PCs) characteristics, such as storage duration, ABO compatibility, dose and source, may have an impact on transfusion responses and outcomes.
- Conditions
- Lymphoma, Multiple Myeloma, Lymphocytic Leukemia, Hodgkin Disease
- Trial name
- TCP (NCT02885038)
- Testing
- Platelet concentrate transfusion
- Volunteers
- 1,101 people
- Sponsor
- Etablissement Français du Sang
Multiple Myeloma
A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
This is a study of pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone in participants with refractory or relapsed and refractory Multiple Myeloma (rrMM), and in combination with carfilzomib and…
- Trial name
- NCT02036502
- Testing
- Pembrolizumab, Lenalidomide, Dexamethasone
- Volunteers
- 77 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
The primary objectives of this study are to determine the safety of single agent Selinexor given with commercial bispecific antibody therapy in patients with Relapsed/Refractory Multiple Myeloma (RRMM) and to determine the MRD…
- Trial name
- NCT06822972
- Testing
- Selinexor 40 mg
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Duke University
Multiple Myeloma
A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D Chimeric antigen receptor (CAR) T-cells in patients with relapsed or refractory multiple myeloma who received…
- Trial name
- NCT05998928
- Testing
- Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Multiple Myeloma and Plasma Cell Neoplasm
Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy such as cyclophosphamide and dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00609167
- Testing
- bortezomib, cyclophosphamide, dexamethasone
- Where
- 2 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Mayo Clinic
Lymphoma, Refractory B-Cell Lymphoma
Study of CAR-T Therapy in Older Patients
This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life.
- Conditions
- Lymphoma, Refractory B-Cell Lymphoma, Lymphoma, B-Cell, DLBCL NOS
- Trial name
- NCT04300998
- Testing
- Activities of Daily Living/ADLs, Instrumental Activity of Daily Living, Timed Up and Go
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma
This phase I/II trial studies the side effects and best dose of vaccine therapy when given with or without cyclophosphamide and to see how well they work in treating patients with multiple myeloma that has come back (recurrent)…
- Trial name
- NCT00450814
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.